Evidence map›Paper›PMID 40079497›Full record

ReviewThe Prostate2025

Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review.

Mark Willy L Mondia, Prem P Batchala, Robert Dreicer, Michael E Devitt, Matthew R McCord, Melike Mut, Jason P Sheehan, David Schiff, Camilo E Fadul

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Prostate, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mark Willy L MondiaDivision of Neuro-Oncology, Department of Neurology, University of Virginia, Charlottesville, Virginia.ORCID 0000-0001-8862-5360
Prem P BatchalaDivision of Nuclear Medicine, Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia.
Robert DreicerDivision of Hematology/Oncology, Departments of Medicine and Urology, University of Virginia, Charlottesville, Virginia.
Michael E DevittDivision of Hematology/Oncology, Departments of Medicine and Urology, University of Virginia, Charlottesville, Virginia.
Matthew R McCordDepartment of Pathology, University of Virginia, Charlottesville, Virginia.
Melike MutDepartment of Neurosurgery, University of Virginia, Charlottesville, Virginia.
Jason P SheehanDepartment of Neurosurgery, University of Virginia, Charlottesville, Virginia.
David SchiffDivision of Neuro-Oncology, Department of Neurology, University of Virginia, Charlottesville, Virginia.
Camilo E FadulDivision of Neuro-Oncology, Department of Neurology, University of Virginia, Charlottesville, Virginia.ORCID 0000-0001-7459-7661

Funding

The authors received no specific funding for this work.
6 · The paper itself

Abstract

backgroundBrain metastases (BMETS) from prostate cancer are rare. Hence, brain imaging in neurologically asymptomatic patients with advanced prostate cancer (aPC) is not routinely performed. Prostate-specific membrane antigen (PSMA) PET/CT uses a radiotracer that binds to prostate cancer epithelial cells and is FDA-approved for initial staging for high-risk prostate cancer, detecting prostate cancer recurrence, and determining eligibility for radionuclide therapy.

methodsWe report six patients with asymptomatic BMETS from aPC found on staging PSMA PET/CT or MRI. Along with cranial MRI, PSMA PET/CT may be useful for detecting asymptomatic intracranial metastasis in select patients with prostate cancer.

resultsBrain metastases were diagnosed in four patients by staging PSMA PET/CT scan-three after systemic disease progression and one during routine surveillance. In two other patients, BMETS were detected using MRI despite negative PSMA PET/CT for brain lesions. All were neurologically asymptomatic. Three patients had undetectable serum prostate-specific antigen (PSA) concentrations; one had neuroendocrine differentiation on histology.

conclusionIn patients with poorly differentiated or neuroendocrine aPC, BMETS may occur without neurologic symptoms and stable PSA. PSMA PET/CT may complement brain MRI for identifying BMETS in these patients.

Indexed as

Brain NeoplasmsMagnetic Resonance ImagingPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAntigens, SurfaceGlutamate Carboxypeptidase IIHumansIncidental FindingsMaleMiddle AgedAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIbrain metastasisMRIPET/CTprostate cancerPSMA

Identifiers

PMID40079497
PMCPMC12068031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.